It describes compositions and formulations containing the N- glycosylation insulin analogues. In certain embodiments, the glycosylated insulin analog were produced in vivo, it is high mannose or fucosylated or non-fucosylated hybrid, one or more N- linked N selected from low mannose or complex N- ...
“mini-proinsulin,” is used to describe a variety of proinsulin analogues containing shortened linker regions such as a dipeptide linker between the A and B chains of insulin. Additional substitutions may also be present such as AlaB30found in porcine...
human insulin or porcine insulin or insulin analogues with a more rapid onset of action. Examples of such insulin analogues are described e.g. in the European patent applications having the publication Nos. EP 214826 (Novo Nordisk A/S), EP 375437 (Novo Nordisk A/S) and EP 383472 (Eli ...
Rapid-acting analogues, regular insulin, NPH insulin, and insulin-like growth factor-I gave positive reactions on intradermal testing. Crystalline zinc insulin (Novolin® U), which contains no monomeric insulin, gave no reaction. However, the first subcutaneous injection of zinc insulin provoked an...
Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness [review]. Diabetes Metab Res Rev. 2004;20:178-188.10.1002/dmrr.447Search in Google Scholar 74 Briscoe VJ, Davis SN. Hypoglycemia in ...
This review describes examples of recent advances in insulin engineering aimed at optimizing the hormone for therapy. Such approaches focus on improvements in the pharmacokinetic properties, storage stability, and feasibility for less intrusive routes of administration [Diabetologia (1997) 40: S 48–S ...
shortened core binding scaffold seen in octreotide and its subsequently developed single and multi-receptor-targeted analogs45. This raises an intriguing question about the extent to which we may uncover similar examples of natural, drug-like compounds in the future, as well as how frequently we ...
Examples of such rapid-acting analogues known in the art are [LysB28, ProB29]-insulin (KP-insulin, the active component of Humalog®), [AspB28]-insulin (Novalog®), and [LysB3, GluB29]-insulin (Apidra®). Although widely used in clinical practice, these analogues exhibit two ...
In these analogues, the B30-amino acid is neutral and, preferably, threonine as in human insulin. German patent application No. 3,327,709 relates to a suspension of crystals of the derivatives described in the above-noted European patent application as well as an aromatic hydroxy compound. ...
Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W (2006) Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry. Anal Chem 78:1897–1903 Article PubMed CAS Google Scholar Thevis M, Loo JA, Loo RR, Schänz...